RESOLUTE (Physician) - Emphysema COPD Research Center

Efficacy and Safety of Benralizumab in Moderate to Very Severe COPD with history of Frequent Exacerbations (RESOLUTE)

This is a multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled, phase III study to evaluate the efficacy and safety of Benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).

Benralizumab is monoclonal antibody directed against IL-5 receptor alpha and causes eosinophil death by apoptosis.

Primary End-Point:

Key inclusion criteria are:

Moderate to severe COPD (FEV1 <= 65%)
≥ 2 exacerbations in 1 year
Eosinophils ≥ 300
LAMA+LABA+ICS x 3 months, ICS dual inhaler for 1 year
CAT ≥ 15
Current or former ≥ 10 pack year smoking

ClinicalTrials.gov Identifier: NCT04053634

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

Efficacy and Safety of Benralizumab in Moderate to Very Severe COPD with history of Frequent Exacerbations (RESOLUTE)

Primary End-Point:

Key inclusion criteria are:

ClinicalTrials.gov Identifier: NCT04053634

Thank You

For Contacting Us!